Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective, multicenter, observational study to assess pregnancy and child outcomes of VDZE pregnancies and to compare these results to anti‐TNF exposed (TNFE) or both immunomodulatory and biologic unexposed (CON IBD) pregnancies

Next Previous
Trial Profile

A retrospective, multicenter, observational study to assess pregnancy and child outcomes of VDZE pregnancies and to compare these results to anti‐TNF exposed (TNFE) or both immunomodulatory and biologic unexposed (CON IBD) pregnancies

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Jun 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vedolizumab (Primary)
  • Indications Inflammatory bowel diseases
  • Focus Adverse reactions
  • Acronyms CONCEIVE

Most Recent Events

  • 10 Jun 2021 Results of systematic review and meta-analysis of four studies assessed to compare maternal and fetal adverse outcomes in pregnancies of women with inflammatory bowel disease exposed to vedolizumab versus those on other treatment, published in the Journal of Gastroenterology and Hepatology.
  • 01 Jan 2020 Results published in the Alimentary Pharmacology and Therapeutics.
  • 13 Nov 2019 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top